UEGweek 2025

AI AI captain! - AI improves histological diagnostics

New rumours about small molecules

New molecules in moderate to severe UC: obefazimod &…

A new oral α4β7 integrin inhibitor - more questions…

Fistulizing perianal disease - still challenging!

Are JAK inhibitors better than their reputation?

If it helps, can we stop it? Drug withdrawel in IBD

Modifying the diet does have an impact on IBD risk!

Timing is everything - surgical intervention in CD

A new oral inhibitor is changing the IL-23 landscape?

T2T in UC - first piece of restrospective evidence

Efficacy of sc induction with guselkumab therapy in UC

JAKis may be safer than you probably think they are!

Finally time to stop the automatic continuation of…

Endlich Zeit das automatisierte 5-ASA Weiterführen zu…

T2T nella CU – prime evidenze retrospettive

Braucht es eine i.v. Induktion bei Biologika?

Perianal CD - it's associated with low infliximab…

Efficacy of Guselkumab in CD patients who lost response…

10 years after the LIR!C trial – the update of the…

To stop or not to stop? That is the question (in…

Is it possible to stop anti-TNF treatment in early CD…

Can we stop Adalimumab in CD patients achieving…

Injecting in fistulas: the never ending story?

Efficacy of guselkumab in patients with inadequate…

Therapy sequence: guselkumab is possible after…

Early treatment with adalimumab does not allow for…

Therapiesequenz: Guselkumab nach Ustekinumab-Versagen…

Ασθενείς με πρόσφατη έναρξη νόσου του Crohn σε…

10 lat po badaniu LIR!C – aktualizacja danych o…

הזרקת תאים לפיסטולה במחלת קרוהן- הסיפור שאינו נגמר?

Possiamo sospendere Adalimumab in pazienti affetti da…

Czy przerywać skuteczne leczenie u pacjentów z chorobą…

Peut-on arrêter un anti-TNF dans la maladie de Crohn…

Obefazimod - a new mechanism of action for the…

IL-23 blockade now also oral

Go for oral anti-α4β7!

Icotrokina - a new oral drug for blocking IL-23

CAR-T cells in refractory UC – a new option for the…

B-cell depletion in refractory ulcerative colitis –…

Mufemilast, αναστολέας της PDE4, για θεραπεία από του…

Obefazimod - Une nouvelle classe thérapeutique pour la…

IL-23 Blockade jetzt auch oral

B-Zell-Depletion bei refraktärer Colitis Ulcerosa -…

Les cellules CAR-T dans la RCH réfractaire – une…

Etrasimod in mild to moderate UC

Long term persistence of ustekinumab in Real-Life…

Short-term (8 weeks) efficacy & safety of obefazimod in…

Obefazimod in moderate to severe UC

Obefazimod induction therapy is effective and well…

Histo-endoscopic endpoint in long-term extension of…

JAK-Inhibitoren sind vielleicht sicherer als Sie…

Efectividad y seguridad en vida real a corto plazo de…

Μακροχρόνια αποτελεσματικότητα της ουστεκινουμάμπης σε…

Etrasimod nella colite ulcerosa da lieve a moderata

Endlich Zeit das automatisierte 5-ASA Weiterführen zu…

Obefazimod nella colite ulcerosa da moderata a grave

Eficacia y seguridad a corto plazo (8 semanas) de…

Guselkumab sc in crohn’s disease with inadequate…

Ustekinumab in perianal Crohn’s disease

Ustékinumab dans la maladie de Crohn ano-périnéale

Guselkumab sc en enfermedad de crohn con respuesta…

IUS as a patient- and environmental-friendly tool in…

Eosinophilic esophagitis doesn’t seem to increase the…

Selection criteria for randomized clinical trials in…

IBD outcome in a large national cohort from spain

When nanoparticles calm down celiac-specific T-cells

AI-endoscopy ready - is it a game changer?

JAKis and pregnany in IBD

Real-life vs clinical trials IBD patients access to…

Vedolizumab - another option for JAKi-induced…

Sigmoid volvulus: an old problem, still waiting for…

Looking for the black sheep pathways

Reassuring safety signals of JAKis in pregnant IBD…

Steroid-sparing effect of upfront Vedolizumab in…

New insights from the GEM trail

Segnali si sicurezza rassicuranti in donne affette da…

Eosinophile Ösophagitis ist kein Risikofaktor für ein…

Verso il verde! L’impatto ecologico del monitoraggio…

פתלת הפרשדון....בעיה מוכרת שעדין מחכה לפתרון

JAK-Inhibitoren und Schwangerschaft bei CED

Wenn Nanopartikel zöliakiespezifische T-Zellen…

Risparmio di steroidi in pazienti con colite indotta da…

Auf der Suche nach den schwarzen Pathway-Schafen

Vedolizumab - eine zusätzliche Therapieoption bei…

Critères de sélection des essais cliniques randomisés…

Co ma wspólnego USG jelit w IBD z ekologią?